Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.76 |
| ▸ | KIT | P10721 | 9/20 | 0.76 |
| ▸ | FLT1 | P17948 | 8/20 | 0.76 |
| ▸ | CSF1R | P07333 | 7/20 | 0.76 |
| ▸ | FLT3 | P36888 | 7/20 | 0.76 |
| ▸ | ABL1 | P00519 | 6/20 | 0.76 |
| ▸ | LCK | P06239 | 6/20 | 0.76 |
| ▸ | LYN | P07948 | 6/20 | 0.76 |
| ▸ | BLK | P51451 | 6/20 | 0.76 |
| ▸ | FLT4 | P35916 | 6/20 | 0.76 |
| ▸ | PLK4 | O00444 | 5/20 | 0.76 |
| ▸ | AURKA | O14965 | 5/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.76 |
| ▸ | MET | P08581 | 5/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.76 |
| ▸ | MARK3 | P27448 | 5/20 | 0.76 |
| ▸ | NEK2 | P51955 | 5/20 | 0.76 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.76 |
| ▸ | STK3 | Q13188 | 5/20 | 0.76 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572745 | 0.94 | KDR (0.76) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3535720 | 0.90 | KIT (0.67) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3533152 | 0.89 | BRAF (0.64) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3568378 | 0.88 | KDR (0.74) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3529804 | 0.87 | KDR (1.00) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3528967 | 0.86 | KDR (0.89) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3527944 | 0.85 | KDR (0.83) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3527326 | 0.84 | KDR (0.88) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3525791 | 0.84 | KDR (0.82) | KDRKITFLT1CSF1RFLT3 | |
| SCHEMBL3528446 | 0.83 | KDR (0.81) | KDRKITFLT1CSF1RFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | claimed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | claimed |
| US-8273736-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | KDR 511/4885KIT 340/4885FLT1 891/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885KIT 188/4885FLT1 613/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KDR 494/4885KIT 188/4885FLT1 613/4885 |
| US-20100069371-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | KDR 494/4885KIT 188/4885FLT1 613/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | KDR 494/4885KIT 188/4885FLT1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.